Attention A T users. To access the menus on this page please perform the following steps. 1. Please switch auto forms mode to off. 2. Hit enter to expand a main menu option (Health, Benefits, etc). 3. To enter and activate the submenu links, hit the down arrow. You will now be able to tab or arrow up or down through the submenu options to access/activate the submenu links.


Quick Links
Veterans Crisis Line Badge
My healthevet badge

VISN 1 New England MIRECC Publications: Medications

Return to main Publications page


Aggarwal, N.K., Rosenheck, R., & Sernyak, M.J. (2012). Prevalence of concomitant oral antipsychotic drug use among patients treated with long-acting intramuscular antipsychotic medications. Journal of Clinical Psychopharmacology, 32(3), 323-328.

Aggarwal, N.K., Rosenheck, R., Woods, S.W., & Sernyak, M.J. (2012). Race and long-acting antipsychotic prescription at a community mental health center: A retrospective chart review. Journal of Clinical Psychiatry, 73(4), 513-517.

Arnold, J.G., Miller, A., Canive, J.M., Rosenheck, R.A., Swartz, M.S., & Mintz, J. (2013). Comparison of outcomes for African Americans, Hispanics, and Non-Hispanic Whites in the CATIE study. Psychiatric Services, 64(6), 570-578.

Barnett, P.G., Scott, J.Y., Krystal, J.H., Rosenheck, R.A. for the CSP 555 Research Study Group. (2012). Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia. Journal of Clinical Psychiatry, 73(5), 696-702.

Barry, D.T., Sofuoglu, M., Kerns, R.D., Wiechers, I.R., & Rosenheck, R.A. (2015). Prevalence and correlates of co-prescribing psychotropic medications with long-term opioid use nationally in the Veterans Health Administration. Psychiatry Research, 227(2-3), 324-332.

Chrisphonte, P., Ostroff, R.B., & Rosenheck, R.A. (2012). Perphenazine suspension: A new, old treatment, side effects and continuous use. Psychiatric Quarterly, 83(3), 335-341.

Forray, A. & Sofuoglu, M. (2014). Future pharmacological treatments for substance use disorders. British Journal of Clinical Pharmacology, 77(2), 382-400.

Fox, H., Sofuoglu, M., & Sinha, R. (2015). Guanfacine enhances inhibitory control and attentional shifting in early abstinent cocaine-dependent individuals. Journal of Psychopharmacology, 29(3), 312-323.

Fusar-Poli, P., Kempton, M.J., & Rosenheck, R.A. (2013). Efficacy and safety of second-generation long-acting injections in schizophrenia: A meta-analysis of randomized-controlled trials. International Clinical Psychopharmacology, 28(2), 57-66.

Gueorguieva, R., Rosenheck, R., & Lin, H. (2012). Joint modeling of longitudinal outcome and interval-censored competing risk dropout in a schizophrenia clinical trial. Journal of the Royal Statistical Society, Series A, 175(2), 417-433.

Herman, A.I., Waters, A.J., McKee, S.A. & Sofuoglu, M. (2012). Effects of pregabalin on smoking behavior, withdrawal symptoms, and cognitive performance in smokers. Psychopharmacology, 220(3), 611-617.

Hermes, E., Harpaz-Rotem, I., & Rosenheck, R. (2014). Diffusion of prazosin treatment for PTSD (Letter to the Editor). American Journal of Psychiatry, 171(1), 117.

Hermes, E. & Rosenheck, R.A. (2012). Choice of randomization to clozapine versus other second generation antipsychotics in the CATIE schizophrenia trial. Journal of Psychopharmacology, 26(9), 1194-2000.

Hermes, E. & Rosenheck, R.A. (2012). Predictors of antipsychotic dose changes in the CATIE schizophrenia trial. Psychiatry Research, 199(1), 1-7.

Hermes, E. & Rosenheck, R. (2014). Prevalence, pharmacotherapy, and clinical correlates of diagnosed insomnia among Veterans Health Administration Service users nationally. Sleep Medicine, 15(5), 508-514.

Hermes, E., Sernyak, M., & Rosenheck, R. (2013). The use of second-generation antipsychotics for post-traumatic stress disorder in a U.S. Veterans Health Administration Medical Center. Epidemiology and Psychiatric Sciences, 23(3), 281-288.

Hermes, E.D., Sernyak, M., & Rosenheck, R. (2012). Impact of a program encouraging the use of generic antipsychotics. The American Journal of Managed Care, 18(8), e307-e314.

Hermes, E.D., Sernyak, M., & Rosenheck, R. (2013). Use of second-generation antipsychotic agents for sleep and sedation: A provider survey. Sleep, 36(4), 597-600.

Hermes, E.D., Sernyak, M.J., & Rosenheck, R.A. (2013). Prescription of second-generation antipsychotics: Responding to treatment risk in real-world practice. Psychiatric Services, 64(3), 238-244.

Hermes, E.D., Sernyak, M.J., & Rosenheck, R.A. (2014). The use of second generation antipsychotics for post-traumatic stress disorder in a US Veterans Health Administration Medical Center. Epidemiology and Psychiatric Sciences, 23(3), 281-288.

Hermes, E.D., Sokoloff, D., Stroup, T.S., & Rosenheck, R.A. (2012). Minimum clinically important difference in the Positive and Negative Syndrome Scale with data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). Journal of Clinical Psychiatry, 73(4), 526-532.

Hoblyn, J.C., Rosenheck, R.A., Leatherman, S., Weil, L., Lew, R., & CSP 555 Investigator Group. (2013). Veteran subjects willingness to participate in schizophrenia clinical trials. Psychiatric Quarterly, 84(2), 209-218.

Hoefer, M., & Petrakis, I. (2014). Prescription drug monitoring programs and buprenorphine maintenance: Clinical considerations. The American Journal on Addictions, 23(6), 616-617.

Iheanacho, T., Issa, M., Marienfeld, C., & Rosenheck, R. (2013). Use of naltrexone for alcohol use disorders in the Veterans Health Administration: A national study. Drug and Alcohol Dependence, 132(1-2), 122-126.

Krystal, J., Pietrzak, R.H., Rosenheck, R.A., Cramer, J.A., Vessicchio, J., Jones, K.M., Huang, G.D., Vertrees, J.E., Collins, J., Krystal, A.D., & VA Cooperative Study #504 Group. (2016). Sleep disturbance in chronic military-related PTSD: Clinical impact and response to adjunctive risperidone in the Veterans Affairs Cooperative Study #504. Journal of Clinical Psychiatry, 77(4), 483-491.

Leatherman, S.M., Liang, M.H., Krystal, J.H., Lew, R.A., Valley, D., Thwin, S.S., Rosenheck, R.A., & CSP 555 Investigators. (2014). Differences in treatment effect among clinical subgroups in a randomized clinical trial of long-acting injectable risperidone and oral antipsychotics in unstable chronic schizophrenia. Journal of Nervous and Mental Disease, 202(1), 13-17.

Liu, H., Wilson, I.B., Goggin, K., Reynolds, N., Simoni, J.M., Golin, C.E., Rosen, M.I., Gross, R., Wagner, G., Remien, R.H., Schneiderman, N., Erlen, J.A., Arnsten, J.H., & Bangsberg, D.R. (2013). MACH14: A multi-site collaboration on ART adherence among 14 institutions. AIDS and Behavior, 17(1), 127–141.

Marienfeld, C., Iheanacho, T., Issa, M., & Rosenheck, R.A. (2014). Long-acting injectable depot naltrexone use in the Veterans’ Health Administration: A national study. Addictive Behaviors, 39(2), 434-438.

Marienfeld, C., & Rosenheck, R.A. (2013). National psychotropic prescription dispensation among dually diagnosed patients. Advances in Dual Diagnosis, 6(1), 34-44.

Martino, S., & Petrakis, I. (2014). Regarding substance using patients and buprenorphine: A primary healthcare challenge. The Bridge: Linking Science and Services, 4(3).

McEvoy, J.P., Byerly, M., Hamer, R.M., Dominik, R., Swartz, M. S., Rosenheck, R.A., Ray, N., Lamberti, J.S., Buckley, P.F., Wilkins, T.M.., & Stroup, T.S. (2014). Effectiveness of paliperidone palmitate vs. haloperidol decanoate for maintenance treatment of schizophrenia: A randomized clinical trial. JAMA, 311(19), 1978-1987.

Milivojevic, V., Sinha, R., Morgan, P.T., Sofuoglu, M., & Fox, H.C. (2014). Effects of endogenous and exogenous progesterone on emotional intelligence in cocaine-dependent men and women who also abuse alcohol. Human Psychopharmacology, 29(6), 589-598.

Mohamed, S., Rosenheck, R., Lyketsos, C.G., Kaczynski, R., Sultzer, D.L., & Schneider, L.S. (2012). Effect of second-generation antipsychotics on caregiver burden in Alzheimer's disease. Journal of Clinical Psychiatry, 73(1), 121-128.

Oliveto, A., Poling, J., Mancino, M.J., Williams, D.K., Thostenson, J., Pruzinsky, R., Gonsai, K., Sofuoglu, M., Gonzalez, G., Tripathi, S., & Kosten, T.R. (2012). Sertraline delays relapse in recently abstinent cocaine-dependent patients with depressive symptoms. Addiction, 107(1), 131-141.

Oncken, C., Arias, A.J., Feinn, R., Litt, M., Covault, J., Sofuoglu, M., & Kranzler, H.R. (2014). Topiramate for smoking cessation: a randomized, placebo-controlled pilot study. Nicotine Tobacco Research, 16(3), 288-296.

Petrakis, I., Desai, N., Gueorguieva, R., Arias, A., O'Brien, E., Jane, J.S., Sevarino, K., Southwick, S., & Ralevski, E. (2016). Prazosin for Veterans with post-traumatic stress disorder (PTSD) and co-morbid alcohol dependence: A clinical trial. Alcoholism, Clinical and Experimental Research, 40(1), 178-186.

Petrakis, I.L., Ralevski, E., Desai, N., Trevisan, L., Gueorguieva, R., Rounsaville, B., & Krystal, J.H. (2012). Noradrenergic vs. serotonergic antidepressant with or without naltrexone for Veterans with PTSD and comorbid alcohol dependence. Neuropsychopharmacology, 37, 996-1004.

Petrakis, I., Sofuoglu, M., & Rosenheck, R. (2015). VA patients with high numbers of opioid prescriptions: A national study of sociodemographic and diagnostic characteristics, health service, and psychotropic medication use. Addictive Disorders & Their Treatment, 14(4), 167-175.

Pietrzak, R.H., Rosenheck, R.A., Cramer, J.A., Vessichio, J.C., Tsai, J., Southwick, S.M., Krystal, J.H., and VA CSP 504 Collaborative Group. (2015). Elucidating the transdiagnostic dimensional structure of trauma-related psychopathology: Findings from the VA cooperative study 504—risperidone treatment for military service-related chronic post-traumatic stress disorder. Journal of Affective Disorders, 172, 331-336.

Ralevski, E., Jane, S.J., O'Brien, E., Edens, E., Arnaout, B., Kerfoot, K., Keegan, K., Weiner, J., Russo, M., & Petrakis, I. (2013). Mecamylamine for treatment of patients with dual diagnoses of depression and alcohol dependence. Journal of Dual Diagnosis 9(4), 301-310.

Ralevski, E., Olivera-Figueroa, L.A., & Petrakis, I. (2014). PTSD and comorbid AUD: A review of pharmacological and alternative treatment options. Substance Abuse and Rehabilitation, 5, 25-36.

Robinson, D.G., Schooler, N.R., Majnu, J., Correll, C.U., Marcy, P.N., Addington, J., Brunette, M.F., Estroff, S.E., Mueser, K.T., Penn, D., Robinson, J., Rosenheck, R.A., Severe, J., Goldstein, A., Azrin, S., Heinssen, R., & Kane, J.M. (2015). Medication prescription practices for the treatment of first episode schizophrenia-spectrum disorders: Data from the National RAISE-ETP Study. American Journal of Psychiatry, 172(3), 237-248.

Rosenheck, R. (2013). Second generation antipsychotics: Evolution of scientific knowledge or uncovering fraud. Epidemiology and Psychiatric Sciences, 22(3), 235-237.

Rosenheck, R.A., Leslie, D.L., Sint, K.J., Lin, H., Li, Y., McEvoy, J.P., Byerly, M.J., Hamer, R.M., Swartz, M.S., & Stroup, T.S. (2016). Cost-effectiveness of long-acting injectable paliperidone palmitate versus haloperidol decanoate in maintenance treatment of schizophrenia. Psychiatric Services, 67(10), 1124-1130.

Rosenheck, R., & Lin, H. (2014). Non-inferiority of perphenazine vs. three second-generation antipsychotics in chronic schizophrenia. Journal of Nervous and Mental Disease, 202(1), 18-24.

Rybin, D., Doros, G., Rosenheck, R., & Lew, R. (2015). The impact of missing data on the results of a schizophrenia study. Pharmaceutical Statistics, 14(1), 4-10.

Sellinger, J.J., Sofuoglu, M., Kerns, R.D., & Rosenheck, R.A. (2015). Combined use of opioids and antidepressants in the treatment of pain: A review of Veterans Health Administration data for patients with pain both with and without co-morbid depression. Psychiatric Quarterly, 87(4), 585-593.

Simoni, J.M., Huh, D., Wilson, I.B., Shen, J., Goggin, K., Reynolds, N.R., Remien, R.H., Rosen, M.I., Bangsberg, D.R., & Liu, H. (2012). Race/Ethnic disparities in ART adherence in the United States: Findings from the MACH14 study. Journal of Acquired Immune Deficiency Syndromes, 60(5), 466-472.

Sofuoglu, M. (2012). Commentary on Ling et al. (2012): The PROMETA treatment does not reduce methamphetamine use. Addiction, 107(2), 370-371.

Sofuoglu, M., Herman, A.I., Li, Y., & Waters, A.J. (2012). Galantamine attenuates some of the subjective effects of intravenous nicotine and improves performance on a Go No-Go task in abstinent cigarette smokers: A preliminary report. Psychopharmacology, 224(3), 413-420.

Sofuoglu, M., Rosenheck, R., & Petrakis, I. (2014). Pharmacological treatment of comorbid PTSD and substance use disorder: Recent progress. Addictive Behaviors, 39(2), 428-433.

Wiechers, I.R., Kirwin, P.D., & Rosenheck, R.A. (2014). Increased risk among older Veterans of prescribing psychotropic medications in the absence of psychiatric diagnoses. American Journal of Geriatric Psychiatry, 22(6), 531-539.

Wiechers, I.R., Leslie, D.L., & Rosenheck, R.A. (2013). Prescribing psychotropic medications to patients without a psychiatric diagnosis. Psychiatric Services, 64(12), 1243–1248.

Xu, K., Krystal, J., Ning, Y., Chun, D.C., He, H., Wang, D., Ke, X., Zhang, X., Ding, Y., Liu, Y., Tan, Y.L., Gueorguieva, R., Wang, Z., Limoncelli, D., Pietrzak, R.H., Petrakis, I., Zhang, X., & Fan, N. (2015). Preliminary analysis of positive and negative syndrome scale in ketamine-associated psychosis in comparison with schizophrenia. Journal of Psychiatric Research, 61, 64-72.

Yonkers, K.A., Forray, A., Nich, C., Carroll, K.M., Hine, C., Merry, B.C., Shaw, H., Shaw, J., & Sofuoglu, M. (2014). Progesterone for the reduction of cocaine use in postpartum women with a cocaine use disorder: A randomized, double-blind, placebo-controlled, pilot study. The Lancet Psychiatry, 1(5), 360-367.

Yoon, G., Kim, S.W., Petrakis, I.L., & Westermeyer, J. (2016). High-dose naltrexone treatment and gender in alcohol dependence. Clinical Neuropharmacology, 39(4), 165-168.

Return to Top


Mehmet Sofuoglu, M.D., Ph.D.

Patricia Sweeney, Psy.D., CPRP
Director for Education

Richard Carson, LCSW
Administrative Officer
203-932-5711 Ext. 4338

Ilan Harpaz-Rotem, Ph.D.
Co-Director for MIRECC Fellowship Program
203-932-5711 Ext. 2599
Co-Director for MIRECC Fellowship Program
203-932-5711 Ext. 7425